These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 35738289)

  • 1. Ethical considerations for the modification of routine human papillomavirus immunisation schedules.
    D'Souza J; Nderitu D
    Lancet Oncol; 2022 Sep; 23(9):1121-1122. PubMed ID: 35738289
    [No Abstract]   [Full Text] [Related]  

  • 2. Bandicoots, bonobos, and boys: papillomavirus and vaccination strategies.
    Grose C
    Pediatrics; 2009 Apr; 123(4):1244-5. PubMed ID: 19336384
    [No Abstract]   [Full Text] [Related]  

  • 3. Moral dilemma(s) in human papillomavirus vaccination - revisiting the role of the herd effect.
    Lehtinen M; Pimenoff VN
    Euro Surveill; 2021 Dec; 26(50):. PubMed ID: 34915973
    [No Abstract]   [Full Text] [Related]  

  • 4. Vaccination against human papillomavirus.
    Mello CF
    Einstein (Sao Paulo); 2013 Dec; 11(4):547-9. PubMed ID: 24488402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The current state of introduction of human papillomavirus vaccination into national immunisation schedules in Europe: first results of the VENICE2 2010 survey.
    Dorleans F; Giambi C; Dematte L; Cotter S; Stefanoff P; Mereckiene J; O'Flanagan D; Lopalco PL; D'Ancona F; Levy-Bruhl D;
    Euro Surveill; 2010 Nov; 15(47):. PubMed ID: 21144444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human papillomavirus vaccination in the European Union/European Economic Area and globally: a moral dilemma.
    Colzani E; Johansen K; Johnson H; Pastore Celentano L
    Euro Surveill; 2021 Dec; 26(50):. PubMed ID: 34915976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human papillomavirus vaccines.
    Satyaprakash A; Creed R; Ravanfar P; Mendoza N
    Dermatol Ther; 2009; 22(2):150-7. PubMed ID: 19335726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inconclusive evidence for non-inferior immunogenicity of two- compared with three-dose HPV immunization schedules in preadolescent girls: A systematic review and meta-analysis.
    Donken R; Knol MJ; Bogaards JA; van der Klis FR; Meijer CJ; de Melker HE
    J Infect; 2015 Jul; 71(1):61-73. PubMed ID: 25709084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination for the prevention of human papillomavirus cancers.
    CA Cancer J Clin; 2020 Jul; 70(4):281-282. PubMed ID: 32639021
    [No Abstract]   [Full Text] [Related]  

  • 10. Introduction of human papillomavirus (HPV) vaccination into national immunisation schedules in Europe: Results of the VENICE 2007 survey.
    King LA; Lévy-Bruhl D; O'Flanagan D; Bacci S; Lopalco PL; Kudjawu Y; Salmaso S;
    Euro Surveill; 2008 Aug; 13(33):. PubMed ID: 18761891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Acute Disseminated Encephalomyelitis Following Human Papillomavirus Vaccination].
    Ferreira D; Almeida M; Nogueira-Silva L; Araújo R; Abreu P
    Acta Med Port; 2020 Nov; 33(11):780-781. PubMed ID: 33160428
    [No Abstract]   [Full Text] [Related]  

  • 12. Immunogenicity of quadrivalent HPV vaccine among girls 11 to 13 Years of age vaccinated using alternative dosing schedules: results 29 to 32 months after third dose.
    Lamontagne DS; Thiem VD; Huong VM; Tang Y; Neuzil KM
    J Infect Dis; 2013 Oct; 208(8):1325-34. PubMed ID: 23901077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An exploration of individual- and population-level impact of the 2-dose HPV vaccination schedule in pre-adolescent girls.
    Donken R; Bogaards JA; van der Klis FR; Meijer CJ; de Melker HE
    Hum Vaccin Immunother; 2016 Jun; 12(6):1381-93. PubMed ID: 27171128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human papillomavirus vaccination: a missed opportunity.
    Pender E; Griffin L
    Br J Dermatol; 2022 Oct; 187(4):584-585. PubMed ID: 35665487
    [No Abstract]   [Full Text] [Related]  

  • 15. Estimate of global human papillomavirus vaccination coverage: analysis of country-level indicators.
    Spayne J; Hesketh T
    BMJ Open; 2021 Sep; 11(9):e052016. PubMed ID: 34475188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COVID-19 Vaccination in Children: Lessons Learned From Human Papillomavirus Vaccination.
    Mansfield LN; Balasuriya L; Brown A
    J Adolesc Health; 2022 Apr; 70(4):525-527. PubMed ID: 35172932
    [No Abstract]   [Full Text] [Related]  

  • 17. The current state of introduction of HPV vaccination into national immunisation schedules in Europe: results of the VENICE 2008 survey.
    Lévy-Bruhl D; Bousquet V; King LA; O'Flanagan D; Bacci S; Lopalco PL; Salmaso S;
    Eur J Cancer; 2009 Oct; 45(15):2709-13. PubMed ID: 19695863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allaying parental concerns about the human papillomavirus vaccine.
    Hutton S; Finlay F
    Paediatr Nurs; 2009 Nov; 21(9):20-3. PubMed ID: 19947104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human papillomavirus vaccination for young survivors of cancer.
    Brewer NT; Huang Q; Kahn BZ
    Lancet Child Adolesc Health; 2022 Jan; 6(1):3-5. PubMed ID: 34767766
    [No Abstract]   [Full Text] [Related]  

  • 20. [Recommendations for the definition of a policy on vaccination against papillomavirus in Mexico. Strategic Advisory Group of Experts of the World Health Organization].
    Lazcano-Ponce E; Salmerón-Castro J; García-Carrancá A; Aranda-Flores C; Madrid-Marina V; Gómez-Altamirano CM; Martínez-Montañez OG
    Salud Publica Mex; 2009; 51(4):336-41. PubMed ID: 19668929
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.